Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
89 Depression Trials near Long Beach, CA
Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
A Phase 2/3 Trial is designed to evaluate SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, PTSD, Others
900 Participants Needed
NMRA-335140 for Depression
Long Beach, CaliforniaThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Personality Disorder, Bipolar, Schizophrenia, Others
650 Participants Needed
Cariprazine for Bipolar Disorder in Youth
Long Beach, CaliforniaThis trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Substance Disorder, Seizures, Others
Must Not Be Taking:Psychotropics, CYP3A4 Inhibitors
380 Participants Needed
BI 1569912 for Depression
Long Beach, CaliforniaThis study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
Participants are put into 4 groups randomly, which means by chance. Three of the 4 groups take different doses of BI 1569912 and 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks.
Participants are in the study for about 2.5 months. During this time, they visit the study site at least 7 times. At the visits, doctors and their staff ask participants about their depression symptoms. At the end of the study, the results are compared between the groups to see whether the treatment works. The doctors also regularly check the general health of participants and take note of any unwanted effects.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Seizure Disorders, Others
224 Participants Needed
NBI-1070770 for Depression
Long Beach, CaliforniaTo evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Unstable Conditions, Neurological, Others
Must Be Taking:Antidepressants
72 Participants Needed
CTC-501 for Depression
Long Beach, CaliforniaThis trial tests pramipexole and ondansetron in patients with major depressive disorder. Pramipexole aims to improve mood by affecting brain chemicals, and ondansetron helps prevent nausea. Pramipexole has been tested in various studies for its efficacy in treating major depression, while ondansetron is being explored for its potential benefits in combination with other treatments. The study compares the treatment over a few months.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
24 Participants Needed
ABX-002 for Depression
Long Beach, CaliforniaThe goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.
This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo).
The study will include the following stages:
1. Screening, Treatment, and Follow-Up ; approximately 35 days
2. 42-day Treatment Period
3. 2-week post dose Safety Follow-up Period
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
230 Participants Needed
NMRA-335140 for Bipolar Depression
Long Beach, CaliforniaThis trial is testing a new medication called NMRA-335140 to see if it can help adults with Bipolar II disorder who are experiencing major depression. The medication aims to improve mood and reduce feelings of depression.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar I, Schizophrenia, Substance Use, Others
Must Not Be Taking:Antidepressants, Mood Stabilizers
60 Participants Needed
Proud & Empowered Program for Bullying in LGBTQ Youth
Long Beach, CaliforniaEfficacy of a Multi-level School Intervention for LGBTQ Youth
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 20
Sex:All
Key Eligibility Criteria
Disqualifiers:Not LGBTQ Student
450 Participants Needed
This trial is testing the efficacy of an investigational drug, SP-624 (study drug) to see how well it might work to treat major depressive disorder.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
456 Participants Needed
NMRA-335140 for Depression
Los Alamitos, CaliforniaThis is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Personality Disorder, Bipolar, Schizophrenia, Others
332 Participants Needed
Psilocybin Analog for Depression
Bellflower, CaliforniaThe purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Suicide Risk, Others
Must Be Taking:Antidepressants
220 Participants Needed
AXS-05 for Depression
Bellflower, CaliforniaThis trial is testing AXS-05, a new medication, to see if it can prevent depression from returning in people who have already improved with it. The study focuses on those with major depressive disorder and aims to maintain their balanced brain chemicals to keep them feeling better. AXS-05 (a combination of dextromethorphan and bupropion) has shown positive results in previous trials for major depressive disorder.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Other AXS-05 Studies, Others
Must Not Be Taking:Auvelity
350 Participants Needed
BHV-7000 for Depression
Torrance, CaliforniaThis trial is testing a new medication called BHV-7000 to see if it is safe and well-tolerated over several months in people with Major Depressive Disorder. The goal is to help those who suffer from severe depression by potentially offering a new treatment option.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:18 - 75
Sex:All
480 Participants Needed
Zelquistinel for Depression
Los Alamitos, CaliforniaThe goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are:
Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)?
What medical problems are observed in participants who take GATE-251?
Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar, Psychotic Disorders, Substance Abuse, Others
Must Not Be Taking:Antidepressants, Antipsychotics, Mood Stabilizers, Others
164 Participants Needed
JNJ-89495120 for Depression
Bellflower, CaliforniaThe purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar, Psychotic Disorders, Substance Use, Others
Must Not Be Taking:Ketamine, Esketamine
124 Participants Needed
Azetukalner for Depression
Torrance, CaliforniaX-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 74
Sex:All
450 Participants Needed
NMRA 335140 for Depression
Torrance, CaliforniaThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
332 Participants Needed
NORA520 for Postpartum Depression
Torrance, CaliforniaThis trial is testing a drug called NORA520 to see if it can help women with severe postpartum depression. The study will check how well the drug works, its side effects, and how much of it gets into the blood and breastmilk. Women in the study will take the drug for a short period.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Psychosis, Others
Must Not Be Taking:Antidepressants, Antipsychotics
90 Participants Needed
BHV-7000 for Bipolar Disorder
Torrance, CaliforniaThe purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:18 - 75
Sex:All
256 Participants Needed
ALTO-203 for Depression
Torrance, CaliforniaThe goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days.
Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will receive ALTO-203 25 μg and 75 μg, as well as placebo. During the multiple-dose period, participants will receive either ALTO-203 25 μg, 75 μg , or placebo. Safety will be assessed over the single dose and 28-day multiple dose periods.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:25 - 64
Sex:All
Key Eligibility Criteria
Disqualifiers:Unstable Medical Condition, Bipolar, Others
Must Not Be Taking:Antidepressants
60 Participants Needed
Pramipexole vs Escitalopram for Depression in HIV
Torrance, CaliforniaA phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes.
An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 70
Sex:All
186 Participants Needed
Seltorexant for Depression
Los Alamitos, CaliforniaThis trial is testing seltorexant to see if it can help people with depression and insomnia who haven't improved with their current antidepressants. Seltorexant aims to improve mood and sleep by acting on certain brain receptors.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 74
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Renal Insufficiency, Cardiovascular, Diabetes, Others
Must Be Taking:SSRIs, SNRIs
752 Participants Needed
Aticaprant for Depression
Bellflower, CaliforniaThis trial is testing if aticaprant can help adults with major depressive disorder who haven't responded well to current antidepressants. The medication works by targeting brain chemicals to improve mood and pleasure.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 64
Sex:All
350 Participants Needed
Psilocybin for Treatment-Resistant Depression
Garden Grove, CaliforniaThis trial is testing a new medication called COMP360 to help people with severe depression that hasn't improved with other treatments. The study involves adults aged 18 and older. Researchers want to see if a single dose of COMP360 can reduce depression symptoms when given with psychological support.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar Disorder, Schizophrenia, Borderline Personality, Others
255 Participants Needed
Lumateperone for Major Depressive Disorder
Pico Rivera, CaliforniaThis trial is testing lumateperone, a medication that may help people with depression who haven't improved with other treatments. The study includes patients diagnosed with Major Depressive Disorder who haven't responded well to their current antidepressants. Lumateperone works by balancing brain chemicals that affect mood, potentially improving depressive symptoms.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Anxiety, Others
Must Be Taking:Antidepressants
470 Participants Needed
Lumateperone for Pediatric Bipolar Depression
Anaheim, CaliforniaThis is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Intellectual Disability, Suicidal Risk, Others
384 Participants Needed
Heart Rate Variability Biofeedback for Depression
Los Angeles, CaliforniaAlthough treatments for depression are effective for many people, not everyone responds to treatment. This lack of treatment response could be due, in part, to the presence of multiple underlying causes of people's depression. This study aims to identify subtypes of depression, based on two factors: how successful people perceive themselves to be at regulating their affect in everyday life; and how much activity in the parasympathetic nervous system increases during moments when people try to regulate. The study involves ambulatory assessment of affect, regulation strategies, and physiological activity in everyday life, in a sample of young adults with remitted major depressive disorder and healthy volunteers. We will study regulation responses in the lab to further determine how subtypes differ in neural, physiological, and behavioral responses. Finally, participants will be randomly assigned to a remote, self-administered biofeedback intervention (vs. control intervention) designed to increase parasympathetic activity and physiological regulation success. While engaging in biofeedback at home for 10 days, participants will simultaneously repeat the ambulatory assessments. This design will allow us to determine the proximal impact of biofeedback on indices of regulation success in everyday life, and whether biofeedback has differential impact on regulation success for different subtypes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 27
Sex:All
Key Eligibility Criteria
Disqualifiers:Autism, Eating Disorder, Substance Use, Others
Must Not Be Taking:Psychotropics
252 Participants Needed
Cognitive Behavioral Immersion for Depression
Los Angeles, CaliforniaThis study will test a new cognitive-behavioral skills training program (CBI) delivered in the metaverse. Although initial evidence suggested CBI was feasible for individuals experiencing depression or anxiety, CBI's effectiveness compared to no intervention has yet to be determined. The intervention may be delivered through virtual reality as well as flat-screen devices, such as a computer, which may also affect CBI's effectiveness.
The study will enroll up to 306 participants with depression. One third of the participants will access CBI through virtual reality, one third of the participants will access CBI through a flat-screen device, and one third of the participants will be asked not to attend CBI sessions for the first 8 weeks of participation of the trial. For both CBI conditions, treatment will be provided over 8 weeks, with a 6-month follow-up period. Enrollment will be ongoing and groups will occur simultaneously.
Potential participants are asked to complete an initial screening and an intake evaluation to determine eligibility. They will then receive 8-weeks of treatment. Participants will complete brief weekly self-report questionnaires throughout their time in the study.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
306 Participants Needed
Cognitive Behavioral Therapy vs Acceptance and Commitment Therapy for Depression
Los Angeles, CaliforniaThis study will compare two psychological treatments for major depressive disorder (MDD): cognitive-behavioral therapy (CBT) and acceptance and commitment therapy (ACT). Both treatments are well-studied and supported by evidence as effective options for people experiencing depression. These treatments will be delivered in an online group format via Zoom.
The study will enroll up to 100 participants with depression. Half of the participants will receive online group CBT and half will receive online group ACT. There will be up to 10 members in each group. For both conditions, treatment will be provided over 8 weeks, with a 6-month follow-up period. Enrollment will be ongoing and groups will occur simultaneously.
Potential participants are asked to complete an initial screening and an intake evaluation to determine eligibility. They will then receive 8-weeks of treatment. Participants will complete self-report questionnaires throughout their time in the study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Other Diagnosis, Suicide Risk, Others
100 Participants Needed
Page 1 of 3+
Frequently Asked Questions
How much do Depression clinical trials in Long Beach, CA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Depression clinical trials in Long Beach, CA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Depression trials in Long Beach, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Long Beach, CA for Depression is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Long Beach, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Depression medical study in Long Beach, CA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Depression clinical trials in Long Beach, CA ?
Most recently, we added PDC-1421 for Depression in Cancer Patients, Collaborative Decision Skills Training for Serious Mental Illness and AFA-281 for Alcoholism to the Power online platform.
What do the "Power Preferred" and "SuperSite" badges mean?
We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.
Which clinics have received Power Preferred and SuperSite awards recruiting for Depression trials in Long Beach, CA ?
The Depression clinics in Long Beach, CA currently recognized as Power Preferred are: Anderson Clinical Research in Redlands, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Viking Clinical Research in Temecula, California Excell Research Inc in Oceanside, California